Cookie Policy

This Cookie Policy is designed to tell you about our practices regarding the collection of information through cookies and other tracking technologies (like gifs, web beacons, etc).

The functionalities for which we use these technologies may include the following:

Assisting you in navigation
Assisting in registering for our events, login, and your ability to provide feedback
Analyzing the use of our products, services or applications
Assisting with our promotional and marketing efforts (including behavioral advertising)
Offering content of third parties (such as social media content)

Below is a detailed list of the cookies we use, with a description. We classify cookies in the following categories:

Strictly Necessary Cookies
Performance Cookies
Functional Cookies
Targeting Cookies

Except where allowed by applicable law, we place cookies after having received your consent through the cookie banner or preference center. You can change your cookie settings per cookie category (except for strictly necessary cookies that are required for the proper functioning of the site) at any time by clicking on the “cookie settings” button below:

Links to other websites

This site may contain links or references to other websites. Please be aware that we do not control the cookies / tracking technologies of other websites and this Cookie Policy does not apply to those websites.

How to Contact Us

If you have any questions, comments, or concerns about this Cookie Policy or the information practices of this site, please use the contact information included in our Privacy Policy.

Changes to This Cookie Policy

If this Cookie Policy changes, the revised policy will be posted on this site. This Cookie Policy was last updated March 3, 2022 .

CONTRAINDICATIONS
TREMFYA^® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA^®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA^® and initiate appropriate therapy.

Infections
TREMFYA^® may increase the risk of infection. Treatment with TREMFYA^® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA^® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA^® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA^® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA^®. Initiate treatment of latent TB prior to administering TREMFYA^®. Monitor patients for signs and symptoms of active TB during and after TREMFYA^® treatment. Do not administer TREMFYA^® to patients with active TB infection.

Immunizations
Prior to initiating TREMFYA^®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA^®.

ADVERSE REACTIONS
Most common (≥1%) adverse reactions associated with TREMFYA^® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.

Please read the full Prescribing Information and Medication Guide for TREMFYA^®. Provide the Medication Guide to your patients and encourage discussion.

cp-82625v3

Cookie Policy

IMPORTANT SAFETY INFORMATION

INDICATIONS

DOSAGE AND ADMINISTRATION

Do you want to continue to [extlink:external-url]?